Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.

There are a variety of routes for academic research to make its way onto the market – through spinouts, through a corporate purchasing a licence to existing research or through a company partnering a university with a view of developing a specific technology, product or service. Pharmaceutical firm Roche has followed none of these direct…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.